NO20075985L - Stabil emulsjonsforbindelse - Google Patents

Stabil emulsjonsforbindelse

Info

Publication number
NO20075985L
NO20075985L NO20075985A NO20075985A NO20075985L NO 20075985 L NO20075985 L NO 20075985L NO 20075985 A NO20075985 A NO 20075985A NO 20075985 A NO20075985 A NO 20075985A NO 20075985 L NO20075985 L NO 20075985L
Authority
NO
Norway
Prior art keywords
stable emulsion
emulsion compound
compound
stable
buffer
Prior art date
Application number
NO20075985A
Other languages
English (en)
Inventor
Naoki Asakawa
Takayuki Doen
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075985(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20075985L publication Critical patent/NO20075985L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en emulsjonssammensetning som innbefatter (A) en forbindelse stabil i et surt område og (B) en buffer. PH justeres til å være mellom ca 3.7 og ca 5.5.
NO20075985A 2005-04-28 2007-11-21 Stabil emulsjonsforbindelse NO20075985L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131807 2005-04-28
PCT/JP2006/309213 WO2006118329A1 (ja) 2005-04-28 2006-04-27 安定な乳化組成物

Publications (1)

Publication Number Publication Date
NO20075985L true NO20075985L (no) 2008-01-25

Family

ID=37308111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075985A NO20075985L (no) 2005-04-28 2007-11-21 Stabil emulsjonsforbindelse

Country Status (24)

Country Link
US (1) US20100016381A1 (no)
EP (2) EP2255785A3 (no)
JP (2) JP5236287B2 (no)
KR (1) KR101321633B1 (no)
CN (2) CN101212986B (no)
AR (1) AR054264A1 (no)
AU (1) AU2006241671B2 (no)
BR (1) BRPI0610029A2 (no)
CA (1) CA2605773C (no)
CR (2) CR9495A (no)
GE (1) GEP20105031B (no)
IL (1) IL186673A (no)
MA (1) MA29487B1 (no)
ME (1) MEP10209A (no)
MX (1) MX2007013407A (no)
MY (1) MY147790A (no)
NO (1) NO20075985L (no)
NZ (1) NZ563225A (no)
PE (1) PE20061437A1 (no)
RU (1) RU2428204C2 (no)
TW (1) TWI462745B (no)
UA (1) UA97346C2 (no)
WO (1) WO2006118329A1 (no)
ZA (1) ZA200710193B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007132825A1 (ja) * 2006-05-15 2009-09-24 武田薬品工業株式会社 医薬
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
CN101229174B (zh) * 2008-01-25 2010-12-15 广东一品红药业有限公司 一种含有盐酸依匹斯汀的抗过敏组合物
US7829513B2 (en) * 2009-03-12 2010-11-09 Greenology Products, Inc. Organic cleaning composition
SG182522A1 (en) 2010-01-27 2012-08-30 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
CN103458929A (zh) * 2011-03-31 2013-12-18 富士胶片株式会社 含有前列腺素的脂肪乳剂
JP5894752B2 (ja) * 2011-03-31 2016-03-30 富士フイルム株式会社 プロスタグランジン含有脂肪乳剤
JP2012214430A (ja) * 2011-03-31 2012-11-08 Fujifilm Corp プロスタグランジン含有脂肪乳剤
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
US20170246136A1 (en) * 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
WO2017196979A1 (en) * 2016-05-10 2017-11-16 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
WO2021252449A1 (en) * 2020-06-08 2021-12-16 Harm Reduction Therapeutics, Inc. Sterilized formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5380737A (en) * 1989-05-04 1995-01-10 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5128339A (en) * 1990-11-01 1992-07-07 Sterling Winthrop Inc. Proteolytic enzyme inhibition method
US5250696A (en) * 1990-11-01 1993-10-05 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylate
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JP2836599B2 (ja) 1996-08-09 1998-12-14 日本電気株式会社 通信制御装置
KR20050071719A (ko) * 1998-03-09 2005-07-07 다케다 야쿠힌 고교 가부시키가이샤 시클로알켄 유도체, 그의 제조 방법 및 용도
CN1170959C (zh) 1998-03-11 2004-10-13 三菱电机株式会社 放电表面处理用压粉体电极
PL353635A1 (en) * 1999-08-06 2003-12-01 Takeda Chemical Industries, Ltd.Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
US6532316B1 (en) * 1999-11-10 2003-03-11 Avanex Corporation Bi-directional polarization-independent optical isolator
JP4863553B2 (ja) * 2000-02-04 2012-01-25 武田薬品工業株式会社 安定な乳化組成物
DE60124504T2 (de) * 2000-02-04 2007-09-20 Takeda Pharmaceutical Co. Ltd. Stabile emulsionszubereitungen
JP2003033195A (ja) * 2001-07-24 2003-02-04 Kyowa Hakko Kogyo Co Ltd テトラヒドロクルクミン類の製造方法
US7960416B2 (en) * 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
US20060134145A1 (en) * 2002-12-06 2006-06-22 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsions
TW200519080A (en) * 2003-10-03 2005-06-16 Ono Pharmaceutical Co Agent containinf (2R)-2-propyloctanic acid as effective component
CA2649628A1 (en) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited Pharmaceutical product

Also Published As

Publication number Publication date
ZA200710193B (en) 2009-07-29
MX2007013407A (es) 2008-01-15
US20100016381A1 (en) 2010-01-21
MA29487B1 (fr) 2008-05-02
EP1875926A1 (en) 2008-01-09
TWI462745B (zh) 2014-12-01
CN101212986B (zh) 2015-01-14
CA2605773C (en) 2014-04-08
CN101212986A (zh) 2008-07-02
MEP10209A (en) 2011-12-20
TW200724159A (en) 2007-07-01
NZ563225A (en) 2011-01-28
AR054264A1 (es) 2007-06-13
CA2605773A1 (en) 2006-11-09
PE20061437A1 (es) 2007-01-25
EP1875926A4 (en) 2013-01-16
RU2007144071A (ru) 2009-06-10
KR101321633B1 (ko) 2013-10-22
KR20080011413A (ko) 2008-02-04
CR20130666A (es) 2014-03-13
UA97346C2 (ru) 2012-02-10
AU2006241671A1 (en) 2006-11-09
CN102670503A (zh) 2012-09-19
IL186673A (en) 2013-08-29
RU2428204C2 (ru) 2011-09-10
IL186673A0 (en) 2008-01-20
WO2006118329A1 (ja) 2006-11-09
EP2255785A2 (en) 2010-12-01
MY147790A (en) 2013-01-31
EP2255785A3 (en) 2013-01-16
CR9495A (es) 2008-02-22
BRPI0610029A2 (pt) 2011-10-11
JPWO2006118329A1 (ja) 2008-12-18
JP2013040215A (ja) 2013-02-28
GEP20105031B (en) 2010-06-25
AU2006241671B2 (en) 2012-06-07
JP5236287B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
NO20075985L (no) Stabil emulsjonsforbindelse
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CO5720212A1 (es) Composicion de anticuerpo her2
BRPI0606379A2 (pt) triazolftalazinas
DK1720909T3 (da) Anti-Abeta antistof
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
RS50510B (sr) Formulacije koje sadrže ekteinascidin i disaharid
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20065451L (no) Dermalt anvendbare flytende formuleringer for a kontrollere parasittartropoder pa dyr.
NO20071823L (no) Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
NO20074805L (no) Fremgangsmate for a identifisere PDE11-modulatorer
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
ATE461189T1 (de) Neue 6-pyridylphenanthridine
NO20052680L (no) Forbedringsmiddel inneholdende brennstoff.
DK1973514T3 (da) Alkohol-i-olie-type-emulsion omfattende et multivalent metalsalt
ATE374346T1 (de) Griff

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application